Amgen's SCLC drug gets orphan status [Seeking Alpha]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Seeking Alpha
The FDA grants orphan drug designation to Amgen's (NASDAQ: AMGN ) treatment for small cell lung cancer. The generic name is bispecific T-cell engager antibody consisting of 2 single chain variable fragment binding domains specific for antigen Delta-like protein 3 (DLL3) and for TCR-associated complex CD3. The generic description could refer to AMG 757. Amgen shares are to $188.26. Click to subscribe to real-time analytics on AMGN Now read: Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund » Subscribe for full text news in your inbox
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
- 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at UBS Group AG from $314.00 to $284.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- 4/10/24 - Form ARS
- AMGN's page on the SEC website